Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

NCT05737706 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT05737706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05737706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 1
Overall status
Terminated
Start date
March 6, 2023
Completion date
March 10, 2025
Enrollment
63 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, colo-rectal cancer, non-small cell lung cancer, pancreatic adenocarcinoma, solid tumor